Collegium Pharmaceutical, Inc. (COLL) dividends
COLL on Nasdaq, Health Care
Sign in to get an email when it declares a dividend.
Collegium Pharmaceutical, Inc. dividend: key facts
Own Collegium Pharmaceutical, Inc.? See exactly what it will pay you
Add your shares to a free DiviCompass portfolio to see your next COLL dividend in your own money, every payment month by month, and an email when it declares. Free for up to 10 holdings, no card needed.
Price history
End-of-day closes on Nasdaq in USD. Dots mark ex-dividend dates.
Dividend history
Declared dividends. Special dividends are marked and excluded from yield and forecasts.
Reported financials
Annual figures from filings, converted to units.
Next 12 months
No dividends expected from the data available.
Estimate confidence: None
Company news
- Collegium Pharmaceutical price target lowered to $41 from $48 at Barclays13 Nov 2026 · TheFly
Barclays lowered the firmâs price target on Collegium Pharmaceutical (COLL) to $41 from $48 and keeps an Overweight rating on the shares.
- Collegium Pharmaceutical reports Q3 EPS $1.96, consensus $1.866 Nov 2026 · TheFly
Reports Q3 revenue $216.3M, consensus $216.03M. Reports Q3 adjusted EBITDA $121.6M vs. $133.0M last year. âWe continued to see strong demand across our ADHD portfolio, supported by expanded commercial...
- Collegium Pharmaceutical price target lowered to $28 from $43 at Piper Sandler6 Nov 2026 · TheFly
Piper Sandler analyst David Amsellem lowered the firmâs price target on Collegium Pharmaceutical (COLL) to $28 from $43 and keeps a Neutral rating on the shares following quarterly results. Theâ¦
- Collegium Pharmaceutical announces $50M accelerated share repurchase program6 Nov 2026 · TheFly
Collegium announced a $50M accelerated share repurchase program as part of its broader capital allocation strategy. The final settlement of the accelerated share repurchase is expected to be completed...
- Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance5 Nov 2026 · GlobeNewsWire
â Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year â â Generated Record JORNAY PM ® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year â â Generated AZSTARYS ...
- Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts29 Oct 2026 · GlobeNewsWire
New multi-year partnership combines youth coach training, an annual Sports for All Summit, and sensory inclusion programs to support neurodivergent children and families New multi-year partnership com...
- Collegium to Report Third Quarter 2026 Financial Results on November 5, 202622 Oct 2026 · GlobeNewsWire
STOUGHTON, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading biopharmaceutical company focused on improving the lives of people living with serious and ...
- Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses21 Oct 2026 · GlobeNewsWire
Seven presentations include pediatric Phase 4 studies of AZSTARYS® (Serdexmethylphenidate/dexmethylphenidate) CII and real-world research of JORNAY PM® (Delayed-Release/Extended-Release Methylphenidat...
Insufficient verified data for a financial-health score
Dividend data and price last updated 16 Nov 2026.